Alumis Inc.
ALMS
Classifica tra le azioni
#10425
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Prezzo delle azioni
$6.15
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$795.38M
Variazione (1 giorno)
-2.61%
Variazione (1 anno)
170.70%
Paese
US
Scambia Alumis Inc. (ALMS)
Categoria
Healthcare
EPS per Alumis Inc. (ALMS)
EPS al March 2025 TTM: $-2.70
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Alumis Inc., l’EPS attuale della società (TTM) è $-2.70. Alla fine del 2023, la società aveva un EPS di $-5.43 un aumento rispetto a rispetto a quello del 2022, che era di $-0.70.
Storico EPS per Alumis Inc. da 2021 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
